Compare iShares MSCI Indonesia ETF (EIDO) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Indonesia ETF vs Novartis AG — how do they compare? iShares MSCI Indonesia ETF trades at $12.2, while Novartis AG trades at $150.94 (market cap $287.66B). The key difference: Novartis AG pays a 3.14% dividend while iShares MSCI Indonesia ETF pays none, and Novartis AG is trading nearer its 52-week high, iShares MSCI Indonesia ETF nearer its low. Which is the better fit depends on your goals.
| EIDO | NVS | |
|---|---|---|
52-Week High | $19.22 | $168.62 |
52-Week Low | $10.80 | $113.50 |
Market Cap | — | $287.66B |
Sector | — | Health |
Enterprise Value | — | $327.68B |
Dividend Yield | — | 3.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The iShares MSCI Indonesia ETF (EIDO) trades at $12.20, up 1.08% on the day, while technical indicators signal a bearish trend with moving averages and overall signals in sell territory. Recent news highlights Indonesia's economic initiatives, including a $15 billion AI-integrated free-meal program and central bank rate hikes to support the rupiah, which directly impacts this country-focused ETF. The fund's dividend was reported to have dropped 27% in 2025, raising questions about underlying asset performance.
The outlook for EIDO is tied to Indonesia's macroeconomic stability and government policy execution. Investment opportunity lies in exposure to Indonesia's growth initiatives, but risks include currency volatility from Bank Indonesia's defensive actions, geopolitical pressures on emerging markets, and the ETF's high-yield but potentially unstable dividend profile.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
